Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salvianolic acid A is a polyphenolic compound and stilbenoid extracted primarily from Salvia miltiorrhiza (Danshen), as well as other plants such as Origanum vulgare. It is recognized for its antioxidant and free radical scavenging properties. Salvianolic acid A has been investigated for cardioprotective effects and is under clinical evaluation in trials such as NCT03908242 (Phase I Study of Continuous Administration of Salvianolic Acid A Tablet). The compound is formed by the combination of danshensu and two molecules of caffeic acid. Its mechanism includes direct antioxidant activity through free radical scavenging and indirect effects via upregulation of antioxidant enzymes such as Nrf2/HO-1 signaling pathway[1][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salvianolic acid a.